Business Wire

The Estée Lauder Companies Launches 2023 Breast Cancer Campaign: Beautifully United to Help End Breast Cancer

29.9.2023 14:00:00 EEST | Business Wire | Press release

Share

For more than 30 years, The Estée Lauder Companies’ Breast Cancer Campaign (The Campaign) has been dedicated to advancing the possibility of a breast cancer-free world for all. This October, The Estée Lauder Companies (ELC) honors Breast Cancer Awareness Month by launching The Campaign in support of the global breast cancer community.

As ELC’s largest corporate social impact program, The Campaign continues to inspire purpose-driven action and is a cornerstone of the company’s social investments in women’s advancement, health and education. Through The Campaign, ELC has also been a longstanding supporter of women in science, research and medicine – funding numerous grants and programs around the world and accelerating opportunities for women in STEM.

The Campaign was founded by Evelyn H. Lauder in 1992 with the launch of the iconic Pink Ribbon. At a time when breast cancer wasn’t spoken about openly, Evelyn and ELC saw an opportunity to bring awareness to the disease and address stigmas in women’s health – inspiring a global movement around The Campaign’s mission to help create a breast cancer-free world for all.

Together, The Estée Lauder Companies’ Breast Cancer Campaign and The Estée Lauder Companies Charitable Foundation (ELCCF) have funded more than $118 million globally for life saving research, education, and medical services, with more than $93 million funding medical research through the Breast Cancer Research Foundation (BCRF). BCRF, also founded by Evelyn Lauder in 1993, is The Campaign’s leading non-profit partner, dedicated to advancing the world’s most promising research to eradicate breast cancer.

In honor of The Campaign’s 30th Anniversary in 2022, ELCCF made a commitment to donate $15 million over five years to BCRF to fund groundbreaking research that will further the goal of reducing breast cancer disparities and improving outcomes. This comprehensive study of the intersection of social determinants of health, comorbidities and the biology of breast cancer in Black women has the potential to significantly impact breast cancer disparities globally. A diverse steering committee, as well as sub-committees, comprised of BCRF experts in disparities from acclaimed academic and medical institutions from across the country have established initial targets critical to identifying the roots of health equity and disparities in breast cancer outcomes. Information from thousands of patients will build this vital data-generating project and is the first step in this multi-year initiative.

This year, The Campaign will:

  • Support 60+ organizations worldwide aligned to the diverse needs of local communities
  • Honor the 20th Anniversary of The Breast Cancer Campaign in China, including the illumination of No.1 Wai Tan Yuan, Shanghai
  • Address disparities that exist across the entire breast cancer landscape
  • Fund medical research and fellowships worldwide
  • Fund medical resources and services including access to mammograms/screenings for vulnerable groups with limited access to healthcare
  • Provide support, therapy and counseling programs
  • Host and convene events to advance education on breast health with key opinion leaders and experts - encouraging stakeholders everywhere to become breast health advocates
  • Issue an Instagram call-to-action (@esteelaudercompanies) on October 1 to engage audiences and raise funds for BCRF using #TimeToEndBreastCancer
  • Engage ELC’s brands: AERIN Beauty, Aveda, Bobbi Brown Cosmetics, Bumble and bumble, Clinique, Darphin, Dr.Jart+, Editions de Parfums Frédéric Malle, Estée Lauder, Jo Malone London, KILIAN PARIS, La Mer, Lab Series, Origins, Smashbox, TOM FORD BEAUTY and Too Faced – with each donating to BCRF and/or local cancer-focused organizations around the world through product sales or flat donations (brand participation varying by market)
  • Illuminate buildings, monuments and landmarks around the world in pink to raise awareness, including Empire State Building, New York City; Eiffel Tower, Paris; Burj Al Arab, United Arab Emirates, among others

"ELC has an unwavering commitment to social impact, with The Breast Cancer Campaign at the forefront of these efforts. I am incredibly proud of the progress we have made ever since my mother, Evelyn Lauder, started The Campaign more than 30 years ago," said William P. Lauder, Executive Chairman, The Estée Lauder Companies Inc. "Our passionate employees, consumers and partners have united to advance possibilities for those affected by this disease. Together, we will continue powering progress, until we realize my mother’s vision of a breast cancer-free world for all."

The call to end breast cancer is more urgent than ever as breast cancer is the most commonly diagnosed cancer worldwide. As long as breast cancer is a life-threatening disease, ELC’s commitment remains unwavering.

To learn more, visit: ELCompanies.com/BreastCancerCampaign and @esteelaudercompanies on Instagram.

About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers, and sellers of quality skin care, makeup, fragrance, and hair care products, and is a steward of luxury and prestige brands globally. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.

ELC-C

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Erin Cohen
The Estée Lauder Companies
ercohen@estee.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development

Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye